Aveo Pharmaceuticals cancer news

Aveo said it will reduce headcount by about 45 (17%) to about 235 and will reduce spending on undisclosed early stage research programs ahead of the potential U.S. launch of tivozanib for renal cell carcinoma (RCC). Aveo said the cuts will come from across the company but will primarily affect research. The company said it does not plan to discontinue any programs and will instead look to partner some, including undisclosed early stage research programs and non-small cell lung cancer (NSCLC) candidate ficlatuzumab. Aveo expects the moves will generate about...